An intellectual property transactions team represented genetics medicine company Homology Medicines in a research and development collaboration with Novartis to use Homology’s gene editing technology to develop new treatments for select ophthalmic and hemoglobin blood diseases.
Under terms of the agreement, Novartis made an upfront payment and an equity investment in Homology. Novartis is also providing funding to advance the drug development programs and explore new uses for Homology’s gene editing technology platform. Homology is also eligible to receive milestone payments from Novartis plus royalties from the sale of the products commercialized under the collaboration.
The Ropes & Gray team was led by intellectual property transactions chair David McIntosh and included IP transactions associates Hannah Freeman and Joshua Jackson (all of Boston).
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.